In­novent de­tails Phase 3 weight loss da­ta from Lil­ly-part­nered GLP-1 in Chi­nese pa­tients

In­novent Bi­o­log­ics has lift­ed the cur­tain on late-stage da­ta from its next-gen­er­a­tion “dou­ble-G” drug in over­weight or obese Chi­nese pa­tients af­ter the com­pa­ny

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.